If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-27. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
== Venture arms == SR One was established in 1985, by SmithKline Beecham to invest in new biotechnology companies and continued operating after GSK was formed; by 2003, GSK had formed another subsidiary, GSK Ventures, to out-license or start new companies around drug candidates that it did not intend to develop further. As of 2003, SR One tended to invest only if the company aligned with GSK's business. In September 2019, Avalon Ventures announced that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK. This includes its transglutaminase 2 (TG2) small molecule program for the treatment of celiac disease.
=== Single-particle measurements === Generally speaking single-particle measurement instruments desorb particles one at a time using a pulsed laser. The process is called laser desorption/ionization (LDI) and is the primary ionization method used for single-particle measurements. The main advantage of using LDI over thermal desorption, is the ability to analyze both non-refractory and refractory (e.g., mineral dust, soot) components of atmospheric aerosols. Laser vaporization allows precise laser firing when individual particles fly through the vaporization zone, and the systems are thus dubbed single particle mass spectrometers (SPMS). Several versions of SPMS have been reported, including the aerosol time-of-flight mass spectrometer (AToFMS), the laser mass analyzer for particles in the airborne state (LAMPAS), particle analysis by laser mass spectrometer (PALMS), the rapid single-particle mass spectrometer (RSMS), the bioaerosol mass spectrometer (BAMS) b194 Steele et al., 2003), the nanoaerosol mass spectrometer (NAMS), the single-particle laser ablation time-of-flight mass spectrometer (SPLAT), the single-particle aerosol mass spectrometer (SPAMS), and laser ablation aerosol particle time-of-flight mass spectrometer (LAAP-ToF-MS). Among the most commons of these instruments is the aerosol time-of-flight mass spectrometer (AToFMS).
Ancient Iranians were among the first to invent a form of cooler utilizing the principles of evaporative cooling and radiative cooling called yakhchāls. These complexes used subterranean storage spaces, a large thickly insulated above-ground domed structure, and outfitted with badgirs (wind-catchers) and series of qanats (aqueducts). Pre-electric refrigeration In modern times, before the invention of the modern electric refrigerator, icehouses and iceboxes were used to provide cool storage for most of the year. Placed near freshwater lakes or packed with snow and ice during the winter, they were once very common. Natural means are still used to cool foods today. On mountainsides, runoff from melting snow is a convenient way to cool drinks, and during the winter one can keep milk fresh much longer just by keeping it outdoors. The word "refrigeratory" was used at least as early as the 17th century.
Due to the reduced water content of the freeze-dried foods that inhibit the growth of microorganisms and prevent enzymatic chemical reactions, these foods are considered shelf-stable and can be kept safe from spoilage for years by preventing the reabsorption of moisture. Freeze-dried foods can be stored at room temperature without the need for refrigeration. Although uncommon compared to most applications, sometimes a seasoning solution is sprayed directly onto ramen noodles to enhance their flavor, prior to being packaged. Powder seasoning packets may also contain anticaking agents and flow agents to prevent the product from clumping into a solid mass.
The concept of border controls has its origins in antiquity. In Asia, the existence of border controls is evidenced in classical texts. The Arthashastra (c. 3rd century BCE) makes mention of passes issued at the rate of one masha per pass to enter and exit the country. Chapter 34 of the Second Book of Arthashastra is concerned with the duties of the Mudrādhyakṣa (lit. 'Superintendent of Seals') who must issue sealed passes before a person could enter or leave the countryside. Passports resembling those issued today were an important part of the Chinese bureaucracy as early as the Western Han (202 BCE-220 CE), if not in the Qin dynasty. They required details such as age, height, and physical features. The passports (zhuan) determined a person's ability to move throughout imperial counties and through points of control. Even children needed passports, but those of one year or less who were in their mother's care may not have needed them.
Sources: en.wikipedia.org
== Valence == Vaccines may be monovalent (also called univalent) or multivalent (also called polyvalent). A monovalent vaccine is designed to immunize against a single antigen or single microorganism. A multivalent or polyvalent vaccine is designed to immunize against two or more strains of the same microorganism, or against two or more microorganisms. The valency of a multivalent vaccine may be denoted with a Greek or Latin prefix (e.g., bivalent, trivalent, or tetravalent/quadrivalent). In certain cases, a monovalent vaccine may be preferable for rapidly developing a strong immune response.
=== New approaches to target biofilms === The application of nanoparticles (NP) are one of novel promising techniques to target biofilms due to their high surface-area-to-volume ratio, their ability to penetrate to the deeper layers of biofilms and the capacity to releasing antimicrobial agents in a controlled way. Studying NP-EPS interactions could provide deeper understanding on how to develop more effective nanoparticles. "smart release" nanocarriers that can penetrate biofilms and be triggered by pathogenic microenvironments to deliver drugs or multifunctional compounds, such as catalytic nanoparticles to aptamers, dendrimers, and bioactive peptides) have been developed to disrupt the EPS and the viability or metabolic activity of the embedded bacteria. Some factors that would alter the potentials of the NP to transport antimicrobial agents into the biofilm include physicochemical interactions of the NP with EPS components, the characteristics of the water spaces (pores) within the EPS matrix and the EPS matrix viscosity. Size and surface properties (charge and functional groups) of the NPs are the major determinants of the penetration in and the interaction with the EPS. Another potential antibiofilm strategy is phage therapy. Bacteriophages, viruses that invade specific bacterial host cells, were suggested to be effective agents in penetrating biofilms.
=== Sales === According to Newell, Half-Life was budgeted with the expectation of lifetime sales of around 180,000 copies. However, it was a surprise hit. In the United States, it debuted at #8 on PC Data's weekly PC game sales chart for the November 15–21 period, with an average retail price (ARP) of $49. It rose to sixth place the following week, before dropping to position 10 for the week ending December 5. During the December 6–12 period, the game climbed back to sixth place; by this time, its ARP had dropped to $36. It placed between sixth and eighth on PC Data's weekly charts through the end of December, and its ARP rose back to $45 by the week ending January 2. PC Data declared Half-Life November's sixth-best-selling PC game in the United States, a position it held for the month of December. While its U.S. sales were below 100,000 copies by November 30, it sold 212,173 copies and earned revenues of $8.6 million in the United States by the end of 1998. In January 1999, Half-Life debuted at #3 on Chart-Track's PC game sales rankings for the United Kingdom, and remained in PC Data's weekly top 10 for the entire month, peaking at #4. By January 19, after two full months of availability, global sales of Half-Life surpassed 500,000 units. In the United States, it was the fifth-best-selling PC game for the month of January. On PC Data's weekly charts, it rose to #2 from February 7–20, with an ARP of $35. Holding a position in the weekly top 10 for the rest of February, it climbed to fourth for the month.
The full-length version with an ATA start, which is transcribed at only 1% the level of other animals with the normal ATG start. A severely truncated version beginning at methionine-76 (Met-76). This version has no predicted signal peptide required for transport out of cytoplasm. A mass spectrometry study reported irisin levels ~3 ng/ml in human plasma, a level on par with other key human hormones, such as insulin. The same study reports that the main form in plasma is the ATA form, as expected for signal peptide presence. There is no comparable study of irisin levels in other animals. In a more recent study, Witmer et al. provide complementary genomic and molecular evidence to demonstrate that Fndc5 (irisin myokine precursor protein) is translated in humans and mice from an overlooked upstream ATG start codon. These findings lend further support to the likely existence of irisin in humans, revealing more plausible mechanisms of Fndc5 protein translation and processing as compared to possible expression from an inefficient mutated ATA start codon.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.